

## News Releases

All Years

Search

Go

[Advanced Search](#)

**NOV 11, 2020**

**Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients**

**NOV 5, 2020**

**Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences**

**AUG 21, 2020**

**Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares**

**AUG 18, 2020**

**Inhibrx Announces Pricing of Initial Public Offering of Common Stock**

**JAN 8, 2020**

**Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40**

Show  per page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?o=65>